Article Data

  • Views 635
  • Dowloads 147

Original Research

Open Access

Clinical benefit of hormonal therapy in advanced ovarian cancer

  • L. Bei1,*,
  • A. V. Silva1
  • A. Petiz2
  • D. Pereira1
  • J. Savva-Bordalo1

1,Department of Medical Oncology

2Department of Gynecology, IPO Porto, Porto (Portugal)

DOI: 10.31083/j.ejgo.2020.01.4967 Vol.41,Issue 1,February 2020 pp.98-101

Published: 15 February 2020

*Corresponding Author(s): L. Bei E-mail:


Objectives: To evaluate the benefit of hormonal therapy in advanced ovarian carcinoma. Materials and Methods: The present authors reviewed the data of advanced epithelial ovarian cancer patients who underwent hormonal therapy between 2009 and 2016. Primary endpoint was clinical benefit. Secondary endpoints were overall response rate, CA 125 response, overall survival, progression-free survival, and toxicity. Results: The authors identified 47 patients. Median age was 61 years. Serous carcinoma was the main histologic subtype (70%). Hormone receptor expression was positive in 23% of patients. Previous to hormonal therapy, 60% of patients were treated with two or more chemotherapy regimens (range 2-8). Hormonal therapy was initiated in 34% of patients due to disease progression and the remaining as maintenance therapy. No relevant toxicity was reported. Progression-free survival was six months (CI 95% 2.1-9.9) and overall survival was 22 months (CI 95% 13.0-31.0). Based on imaging response criteria, one patient had complete response, 70% had stable disease, and 19% progressed on the first evaluation. Overall clinical benefit was 72%. Discussion: Clinical benefit was superior to the reported in the literature, probably related to its maintenance use between chemotherapy treatments. More prospective studies are needed to determine the real advantage of hormonal therapy in advanced ovarian cancer vs. clinical surveillance, mainly in the maintenance setting, as well as its correlation with hormone receptor expression.


Ovarian cancer; Hormonal therapy; Letrozole; Tamoxifen; Megestrol.

Cite and Share

L. Bei,A. V. Silva,A. Petiz,D. Pereira,J. Savva-Bordalo. Clinical benefit of hormonal therapy in advanced ovarian cancer. European Journal of Gynaecological Oncology. 2020. 41(1);98-101.


[1] EUCAN Cancer Factsheets: “Ovary”. Available at: eucan/CancerOne.aspx?Cancer=27&Gender=2

[2] Surveillance End Results Program (SEER). Available at: https://seer.

[3] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[4] Dunton C.J.: “Management of treatment-related toxicity in advanced ovarian cancer”. Oncologist, 2002, 7, 11.

[5] Fotopoulou C.: “Limitations to the use of carboplatin-based therapy in advanced ovarian cancer”. Eur. J. Cancer Supplements, 2014, 12, 13.

[6] Hanker L.C., Loibl S., Burchardi N., Pfisterer J., Meier W., PujadeLauraine E., et al.: “The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinumbased therapy”. Ann. Oncol., 2012; 23, 2605.

[7] Langdon S.P., Crew A.J., Ritchie A.A., Muir M, Wakeling A., Smyth J.F., et al.: “Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model”. Eur. J. Cancer, 1994, 30a, 682.

[8] Simpkins F., Hevia-Paez P., Sun J., Ullmer W., Gilbert C.A., da Silva T., et al.: “Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo”. Clin. Cancer Res., 2012, 18, 5911.

[9] Simpkins F., Garcia-Soto A., Slingerland J.: “New insights on the role of hormonal therapy in ovarian cancer”. Steroids, 2013, 78, 530.

[10] Bowman A., Gabra H., Langdon S.P., Lessells A., Stewart M., Young A., et al.: “CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup”. Clin Cancer Res., 2002, 8, 2233.

[11] del Carmen M.G., Fuller A.F., Matulonis U., Horick N.K., Goodman A., Duska L.R., et al.: “Phase II trial of anastrozole in women with asymptomatic mullerian cancer”. Gynecol. Oncol., 2003, 91, 596.

[12] Hatch K.D., Beecham J.B., Blessing J.A., Creasman W.T.: “Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients”. Cancer, 1991, 68, 269.

[13] Papadimitriou C.A., Markaki S., Siapkaras J., Vlachos G., Efstathiou E., Grimani I., et al.: “Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study”. Oncology, 2004, 66, 112.

[14] Ramirez P.T., Schmeler K.M., Milam M.R., Slomovitz B.M., Smith J.A., Kavanagh J.J., et al.: “Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum”. Gynecol. Oncol., 2008, 110, 56.

[15] Schwartz P.E., Keating G., MacLusky N., Naftolin F., Eisenfeld A.: “Tamoxifen therapy for advanced ovarian cancer”. Obstet. Gynecol., 1982, 59, 583.

[16] Smyth J.F., Gourley C., Walker G., MacKean M.J., Stevenson A., Williams A.R., et al.: “Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients”. Clin. Cancer Res., 2007, 13, 3617.

[17] Weiner S.A., Alberts D.S., Surwit E.A., Davis J., Grosso D.: “Tamoxifen therapy in recurrent epithelial ovarian carcinoma”. Gynecol. Oncol., 1987, 27, 208.

[18] Gershenson D.M., Sun C.C., Iyer R.B., Malpica A.L., Kavanagh J.J., Bodurka D.C., et al.: “Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum”. Gynecol. Oncol., 2012, 125, 661.

[19] Gershenson D.M., Sun C.C., Bodurka D., Coleman R.L., Lu K.H., Sood A.K., et al.: “Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant”. Gynecol. Oncol., 2009, 114, 48.

[20] Grabowski J.P., Harter P., Heitz F., Pujade-Lauraine E., Reuss A., Kristensen G., et al.: “Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase”. Gynecol. Oncol., 2016, 140, 457.

[21] Schmeler K.M., Sun C.C., Bodurka D.C., Deavers M.T., Malpica A., Coleman R.L., et al.: “Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum”. Gynecol. Oncol., 2008, 108, 510.

[22] Gershenson D.M., Bodurka D.C., Coleman R.L., Lu K.H., Malpica A., Sun C.C.: “Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum”. J Clin Oncol., 2017, 35, 1103.

[23] Williams C., Simera I., Bryant A.: “Tamoxifen for relapse of ovarian cancer”. Cochrane Database Syst. Rev., 2010, 3, CD001034.

[24] Verma S., Alhayki M., Le T., Baines K., Rambout L., Hopkins L., et al.: “Phase II study of exemestane in refractory ovarian cancer”. J. Clin. Oncol., 2006, 24, 5026.

[25] George A., McLachlan J., Tunariu N., Della Pepa C., Migali C., Gore M., et al.: “The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole”. BMC Cancer, 2017, 17, 456.

[26] Sikic B.I., Scudder S.A., Ballon S.C., Soriero O.M., Christman J.E., Suey L., et al.: “High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group”. Semin. Oncol., 1986, 13, 26.

[27] Veenhof C., van der Burg M., Nooy M., Aalders J.G., Pecorelli S., Oliveira C.F., et al.: “Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma”. Eur. J. Cancer, 1994, 30, 697.

[28] Wilailak S., Linasmita V., Srisupundit S.: “Phase II study of highdose megestrol acetate in platinum-refractory epithelial ovarian cancer”. Anticancer Drugs, 2001, 127, 19.

[29] Bonaventura A., O’Connell R.L., Mapagu C., Beale P.J., McNally O.M., Mileshkin L.R., et al.: “Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptor-positive platinum-resistant or -refractory recurrent ovarian cancer. Int. J. Gynecol. Cancer, 2017, 27, 900.

[30] Day R..”Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project”. Annals N.Y. Acad. Sci., 2001, 949, 143.

[31] Cuzick J., Forbes J., Edwards R., Baum M., Cawthorn S., Coates A., et al.: “First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial”. Lancet, 2002, 360, 817.

[32] Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al.: “Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study”. J. Natl. Cancer Inst., 1998, 90,1371.

[33] Swerdlow A.J., Jones M.E.: “Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study”. J. Natl. Cancer Inst., 2005, 97, 375.

[34] Howell A, Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al.: “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer”. Lancet, 2005, 365, 60.

[35] Sehdev S., Martin G., Sideris L., Lam W., Brisson S.: “Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer”. Curr. Oncol., 2009, 16, S14.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time